Answers are grounded in this paper and cite their sources.
Analysis reveals MEQ antimicrobial peptide effectively targets bacterial infections, suggesting improved treatment options for multi-drug resistance.
Amino Acid Sequence: The MEQ Antimicrobial Peptide (AMP) is designed to combat multi-drug resistant (MDR) bacterial infections. It consists of a specific sequence of amino acids that form an amphipathic structure, allowing the peptide to interact with and disrupt bacterial cell membranes. The sequence is optimized for broad-spectrum activity against various bacterial pathogens. Modifications: The peptide may include modifications such as cyclization or D-amino acid substitution to enhance stability, reduce susceptibility to proteolytic degradation, and extend its half-life. Additionally, modifications can enhance the peptide’s selectivity for bacterial over mammalian cells, reducing potential cytotoxicity.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: